A PHASE I, OPEN-LABEL, NON-RANDOMIZED, DOSE-ESCALATING, SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC AND EFFICACY STUDY OF TAS-120 IN PATIENTS WITH ADVANCED SOLID TUMORS.

Trial Profile

A PHASE I, OPEN-LABEL, NON-RANDOMIZED, DOSE-ESCALATING, SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC AND EFFICACY STUDY OF TAS-120 IN PATIENTS WITH ADVANCED SOLID TUMORS.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Feb 2018

At a glance

  • Drugs TAS 120 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Taiho Pharmaceutical
  • Most Recent Events

    • 05 Feb 2018 Planned End Date changed from 31 Dec 2017 to 31 Mar 2019.
    • 12 Sep 2017 Results (n=36 as of 3 Apr 2017) presented at the 42nd European Society for Medical Oncology Congress
    • 09 Aug 2016 Planned number of patients changed from 212 to 142.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top